- Home
- URGN vs OWLS Comparison
URGN vs OWLS Comparison
Compare URGN & OWLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- OWLS
- Stock Information
- Founded
- URGN 2004
- OWLS 2010
- Country
- URGN United States
- OWLS Taiwan
- Employees
- URGN N/A
- OWLS N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- OWLS Computer Software: Prepackaged Software
- Sector
- URGN Health Care
- OWLS Technology
- Exchange
- URGN Nasdaq
- OWLS Nasdaq
- Market Cap
- URGN 830.4M
- OWLS 865.2M
- IPO Year
- URGN 2017
- OWLS N/A
- Fundamental
- Price
- URGN $20.62
- OWLS $9.42
- Analyst Decision
- URGN Strong Buy
- OWLS
- Analyst Count
- URGN 8
- OWLS 0
- Target Price
- URGN $28.50
- OWLS N/A
- AVG Volume (30 Days)
- URGN 921.6K
- OWLS 409.9K
- Earning Date
- URGN 11-06-2025
- OWLS 01-01-0001
- Dividend Yield
- URGN N/A
- OWLS N/A
- EPS Growth
- URGN N/A
- OWLS N/A
- EPS
- URGN N/A
- OWLS N/A
- Revenue
- URGN $94,238,000.00
- OWLS $7,569,630.00
- Revenue This Year
- URGN $36.41
- OWLS N/A
- Revenue Next Year
- URGN $118.04
- OWLS N/A
- P/E Ratio
- URGN N/A
- OWLS N/A
- Revenue Growth
- URGN 10.85
- OWLS 18.29
- 52 Week Low
- URGN $3.42
- OWLS $7.48
- 52 Week High
- URGN $21.71
- OWLS $90.00
- Technical
- Relative Strength Index (RSI)
- URGN 63.69
- OWLS N/A
- Support Level
- URGN $19.17
- OWLS N/A
- Resistance Level
- URGN $21.00
- OWLS N/A
- Average True Range (ATR)
- URGN 1.12
- OWLS 0.00
- MACD
- URGN 0.35
- OWLS 0.00
- Stochastic Oscillator
- URGN 83.19
- OWLS 0.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About OWLS OBOOK Holdings Inc. Class A Common Shares
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.